Activated human microglia stimulate neuroblastoma cells to upregulate production of beta amyloid protein and tau: Implications for Alzheimer's disease pathogenesis

Neurobiology of Aging

Volumn 36, Issue 1, 2015, Pages 42-52

  Lee, Moonhee ^a   McGeer, Edith ^a   McGeer, Patrick L ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Amyloid precursor protein; Aspirin; Glutathione; Ibuprofen; IL 10; Neurofibrillary tangles; Tauopathy

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA SECRETASE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; GAMMA INTERFERON; GLUTATHIONE; IBUPROFEN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; SODIUM SULFIDE; TAU PROTEIN; AMYLOID BETA-PROTEIN (1-42); NONSTEROID ANTIINFLAMMATORY AGENT; PEPTIDE FRAGMENT;

ADULT; ALZHEIMER DISEASE; ARTICLE; CELL ACTIVATION; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; MICROGLIA; NERVE CELL DIFFERENTIATION; NEUROBLASTOMA CELL; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN SYNTHESIS; UPREGULATION; YOUNG ADULT; CELL CULTURE; METABOLISM; MOLECULARLY TARGETED THERAPY; NEUROBLASTOMA; PHYSIOLOGY; TUMOR CELL CULTURE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELLS, CULTURED; HUMANS; INTERLEUKIN-1BETA; INTERLEUKIN-6; MICROGLIA; MOLECULAR TARGETED THERAPY; NEUROBLASTOMA; PEPTIDE FRAGMENTS; TAU PROTEINS; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 84920446120     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2014.07.024     Document Type: Article

References (39)

1. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M., Cooper N.R., Eikelenboom P., Emmerling M., Fiebich B.L., Finch C.E., Frautschy S., Griffin W.S., Hampel H., Hull M., Landreth G., Lue L., Mrak R., Mackenzie I.R., McGeer P.L., O'Banion M.K., Pachter J., Pasinetti G., Plata-Salaman C., Rogers J., Rydel R., Shen Y., Streit W., Strohmeyer R., Tooyoma I., Van Muiswinkel F.L., Veerhuis R., Walker D., Webster S., Wegrzyniak B., Wenk G., Wyss-Coray T. Inflammation and Alzheimer's disease. Neurobiol. Aging 2000, 21:383-421.
2. Andrews P.W., Damjanov I., Simon D., Banting G.S., Carlin C., Dracopoli N.C., Fogh J. Pluripotent embryonal carcinoma clones derived from the human teratocarcinoma cell line Tera-2. Differentiation invivo and invitro. Lab. Invest. 1984, 50:147-162.
3. Banati R.B., Gehrmann J., Schubert P., Kreutzberg G.W. Cytotoxicity of microglia. Glia 1993, 7:111-118.
4. Bateman R.J., Xiong C., Benzinger T.L., Fagan A.M., Goate A., Fox N.C., Marcus D.S., Cairns N.J., Xie X., Blazey T.M., Holtzman D.M., Santacruz A., Buckles V., Oliver A., Moulder K., Aisen P.S., Ghetti B., Klunk W.E., McDade E., Martins R.N., Masters C.L., Mayeux R., Ringman J.M., Rossor M.N., Schofield P.R., Sperling R.A., Salloway S., Morris J.C. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N.Engl. J. Med. 2012, 367:793-804.
5. Brody D.L., Magnoni S., Schwetye K.E., Spinner M.L., Esparza T.J., Stocchetti N., Zipfel G.J., Holtzman D.M. Amyloid-beta dynamics correlate with neurological status in the injured human brain. Science 2008, 321:1221-1224.
6. Buchhave P., Minthon L., Zetterberg H., Wallin A.K., Blennow K., Hansson O. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch. Gen. Psychiatry 2012, 69:98-106.
7. Colton C.A. Heterogeneity of microglial activation in the innate immune response in the brain. J.Neuroimmune Pharmacol. 2009, 4:399-418.
8. Deshpande A., Mina E., Glabe C., Busciglio J. Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons. J.Neurosci. 2006, 26:6011-6018.
9. Goedert M., Spillantini M.G. Acentury of Alzheimer's disease. Science 2006, 314:777-781.
10. Griffin W.S., Stanley L.C., Ling C., White L., MacLeod V., Perrot L.J., White C.L., Araoz C. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A 1989, 86:7611-7615.
11. Grundke-Iqbal I., Iqbal K., Tung Y.C., Quinlan M., Wisniewski H.M., Binder L.I. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. U.S.A 1986, 83:4913-4917.
12. Hardy J., Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol. Sci. 1991, 12:383-388.
13. Hatashita S., Yamasaki H. Diagnosed mild cognitive impairment due to Alzheimer's disease with PET biomarkers of beta amyloid and neuronal dysfunction. PloS One 2013, 8:e66877.
14. Holtzman D., Morris J.C., Goate A.M. Alzheimer's disease: the challenge of the second century. Sci. Transl. Med. 2011, 3:77sr1. 2011.
15. In t' Veld B.A., Ruitenberg A., Hofman A., Launer L.J., van Duijn C.M., Stijnen T., Breteler M.M., Stricker B.H. Nonsteroidal anti-inflammatory drugs and the risk of Alzheimer's disease. N.Engl. J. Med. 2001, 345:1515-1521.
16. Kim H.J., Chae S.C., Lee D.K., Chromy B., Lee S.C., Park Y.C., Klein W.L., Krafft G.A., Hong S.T. Selective neuronal degeneration induced by soluble oligomeric amyloid beta protein. FASEB J. 2003, 17:118-120.
17. Lee M., Schwab C., Yu S., McGeer E., McGeer P.L. Astrocytes produce the antiinflammatory and neuroprotective agent hydrogen sulfide. Neurobiol. Aging 2009, 30:1523-1534.
18. Lee M., Sparatore A., Del Soldato P., McGeer E., McGeer P.L. Hydrogen sulfide-releasing NSAIDs attenuate neuroinflammation induced by microglial and astrocytic activation. Glia 2010, 58:103-113.
19. Lee M., Suk K., Kang Y., McGeer E., McGeer P.L. Neurotoxic factors released by stimulated human monocytes and THP-1 cells. Brain Res. 2011, 1400:99-111.
20. Li Y., Liu L., Barger S.W., Griffin W.S. Interleukin-1 mediates pathological effects of microglia on tau phosphorylation and on synaptophysin synthesis in cortical neurons through a p38-MAPK pathway. J.Neurosci. 2003, 23:1605-1611.
21. Lobert S., Hiser L., Correia J.J. Expression profiling of tubulin isotypes and microtubule-interacting proteins using real-time polymerase chain reaction. Methods Cell Biol. 2010, 95:47-58.
22. Lorenzo A., Yankner B.A. Beta amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc. Natl. Acad. Sci. U.S.A 1994, 125:12243-12247.
23. McGeer P.L., Akiyama H., Itagaki S., McGeer E.G. Immune response in Alzheimer's disease. Can J. Neurol. Sci. 1989, 16:516-527.
24. McGeer P.L., McGeer E.G. The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy. Acta Neuropathol. 2013, 126:479-497.
25. McKee A.C., Stern R.A., Nowinski C.J., Stein T.D., Alvarez V.E., Daneshvar D.H., Lee H.S., Wojtowicz S.M., Hall G., Baugh C.M., Riley D.O., Kubilus C.A., Cormier K.A., Jacobs M.A., Martin B.R., Abraham C.R., Ikezu T., Reichard R.R., Wolozin B.L., Budson A.E., Goldstein L.E., Kowall N.W., Cantu R.C. The spectrum of disease in chronic traumatic encephalopathy. Brain 2013, 136:43-64.
26. Ono K., Condron M.M., Teplow D.B. Structure-neurotoxicity relationships of amyloid beta-protein oligomers. Proc. Natl. Acad. Sci. U.S.A 2009, 106:14745-14750.
27. Prestia A., Caroli A., van der Flier W.M., Ossenkoppele R., Van Berckel B., Barkhof F., Teunissen C.E., Wall A.E., Carter S.F., Schöll M., Choo I.H., Nordberg A., Scheltens P., Frisoni G.B. Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. Neurology 2013, 80:1048-1056.
28. Rogers J., Cooper N.R., Webster S., Schultz J., McGeer P.L., Styren S.D., Civin W.H., Brachova L., Bradt B., Ward P., Lieberburg I. Complement activation by beta-amyloid in Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A 1992, 89:10016-10020.
29. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 2001, 81:741-766.
30. Singh U.S., Pan J., Kao Y.L., Joshi S., Young K.L., Baker K.M. Tissue transglutaminase mediates activation of RhoA and MAP kinase pathways during retinoic acid-induced neuronal differentiation of SH-SY5Y cells. J.Biol. Chem. 2003, 278:391-399.
31. Spillantini M.G., Goedert M. Tau pathology and neurodegeneration. Lancet Neurol. 2013, 12:609-622.
32. Stewart W.F., Klawas C., Corrada M., Metter E.J. Risk of Alzheimer disease and duration of NSAID use. Neurology 1997, 48:626-632.
33. Uberti D., Rizzini C., Spano P.F., Memo M. Characterization of tau proteins in human neuroblastoma SH-SY5Y cell line. Neurosci. Lett. 1997, 235:149-153.
34. Villemagne V.L., Burnham S., Bourgeat P., Brown B., Ellis K.A., Salvado O., Szoeke C., Macaulay S.L., Martins R., Maruff P., Ames D., Rowe C.C., Masters C.L. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 2013, 12:357-367. Australian Imaging Biomarkers and Lifestyle (AIBL) Research Group.
35. Vlad S.C., Miller D.R., Kowall N.W., Felson D.T. Protective effects of NSAIDs on the development of Alzheimer disease. Neurology 2008, 70:1672-1677.
36. 11C] Pittsburgh compound B data. Ann. Neurol. 2011, 70:857-861.
37. Xia W., Yang T., Shankar G., Smith I.M., Shen Y., Walsh D.M., Selkoe D.J. Aspecific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Archiv Neurol. 2009, 66:190-199.
38. Yasojima K., McGeer E.G., McGeer P.L. Relationship between beta amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain. Brain Res. 2001, 919:115-121.
39. Zandi P.P., Anthony J.C., Hayden K.M., Mehta K., Mayer L., Breitner J.C. Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County study. Neurology 2002, 59:880-886. Cache County Study Investigators.